echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Dr. Shen Yuelei: In 2020, CRO company to the front of new drug research and development?

    Dr. Shen Yuelei: In 2020, CRO company to the front of new drug research and development?

    • Last Update: 2020-08-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Introduction: In recent years, the emerging VIC company, will commission CRO company to complete all the steps of new drug research and development, so that CRO company's role becomes heavy.
    traditional thinking, the research and development of new drugs is mainly dominated by Party A, CRO company (Party B) is generally at the request of Party A to complete some supplementary work.
    and in recent years, the emerging VIC company, will commission CRO company to complete all the steps of new drug development, so that CRO's role becomes more important. Dr. Shen Yuelei,
    , Chairman and General Manager of 10Osetu, risk-sharing, benefit sharing will be the future trend of new drug research and development to find targets and the best drug candidates, is a long and repeated process, need to complete a large number of experiments, the cost is difficult to predict.
    Party A needs to save money, and for profit-oriented CRO is not willing to do outside the task of investment, there will be a "almost" mentality, which is also leading to the clinical stage failure rate remains high an important reason.
    , although, to meet customer requirements, CRO companies must have a variety of professional senior personnel.
    however, in order to reduce costs, the overall salary level of the general CRO company is not enough to recruit senior talent, resulting in CRO companies can not high-quality to meet the requirements of Party A is also common.
    a "risk-sharing, benefit-sharing" will be the future trend of new drug research and development.
    this would make CRO more willing to double-verify targets and candidates through a large number of experiments, and Party A will have more confidence in pushing the product in its hands to the clinic.
    the current success rate of a clinical second phase (POC) of an antibody molecule is less than 30%, and the success rate from IND to NDA is only about 10%.
    pre-clinical research and development to do solid, will greatly improve the success rate of clinical trials, will save a lot of investment and clinical resources.
    cro companies are not enough investment, drug research and development can ultimately be the key to success.
    picture source: Roche's official website pharmaceutical company, CRO, VC game and the new machine drug Ming biological incubation cornerstone pharmaceutical industry, Via bio-incubation dozens of enterprises, hundred Osetu incubation and medicine, these companies are basically no longer the traditional CRO company, but represents the trend of drug cooperation research and development.
    this cooperation, will allow more top talents to join THE CRO, through their own intellectual input, the use of CRO company's complete research and development platform, with Party A to participate in the development of many drugs, to achieve their economic and social value of the return, of course, also improve the cro company's overall technical and service level.
    as Party A, most hope to get a higher clinical success rate of candidate drugs.
    when working with CRO companies, if it is purely a service for cash, it may not be the best candidate drug molecules, which increases clinical risk.
    if it can achieve interest binding with Party B, we can achieve a win-win situation.
    CRO companies can also take the first step, and constantly develop new products, through the sale or cash plus equity, transfer to the clinical stage company, to achieve the early market of the drug.
    as CRO company, the biggest advantage is the scale, through a series of experiments, repeated validation, and peer-to-peer comparison before clinical, to achieve the possibility of finding best-in-class, or even new target drugs.
    is generally considered to be a pharmaceutical company or Abiotech.
    and in the U.S. experience, there are also a group of important clients are investment institutions, especially those with business experience and expertise.
    investment institutions after seeing a good development platform or product, it is possible to take some targets and products directly, using CRO company's experience in drug development stage, directly to the IND stage, and then recruit clinical team.
    this way, the investment company's investment has basically translated into the company's valuation, that is, floor price investment, it is easier to achieve a rapid increase in the company's value.
    and via biorealis actually make a very good combination of services and investment.
    in the next five years, we will see a big change in the entire biopharmaceutical industry.
    even in China, Biotech company will be set up by investment companies, from the introduction of domestic rights and interests of products, to a new target of global rights and interests cooperative development, A and B both sides "benefit sharing risk sharing" transformation.
    especially in the post-PD-1 era, the target becomes scattered, the understanding and verification of the target becomes more important and urgent, but also a company has no competitiveness key.
    in short, the trend for CRO companies, especially CRO companies involved in early new drug development, to move from behind the scenes to the front stage will be blurred.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.